ArticleCentral European journal of urology2011
Immunohistochemical detection of angiotensin AT 1 and AT 2 receptors in prostate cancer.
Article in Central European journal of urology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
- Significance of atypical small acinar proliferation and extensive high-grade prostatic intraepithelial neoplasm in clinical practice.Central European journal of urology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe human prostate gland contains all the compounds of the renin-angiotensin system (RAS), including AT1 and AT2 angiotensin receptors. The role of local RAS in the prostate pathology is recently discussed. The aim of the present study was the evaluation of AT1 and AT2 expressions in human prostate cancers. MATERIAL AND
methodsThe investigation was performed in 20 paraffin-embedded needle biopsy specimens from routine diagnostic prostate cancer biopsies. The specimens were stained with hematoxylin and eosin and immunostained with anti-AT1 and anti-AT2 antibodies. For visualization of primary antibodies, the streptavidin-biotin-peroxidase technique was applied. The expression of both receptor proteins was evaluated quantitatively using image analysis method.
resultsThe positive immunostaining with both anti- AT1 and anti-AT2 antibodies can be found in stromal as well as epithelial structures. The results of quantitative evaluation showed the positive correlation between AT1 and AT2 expressions in neoplastic epithelium and overexpression of both AT1 and AT2 in neoplastic epithelium of Gleason grade 2, but not in cancerous structures of Gleason grades 3-5.
conclusionsThe data on AT1 and AT2 receptor expressions may suggest the involvement of RAS in prostate cancerogenesis. Moreover, the persistence of AT1 receptors in prostate cancer speaks in favor of attempts to use of AT1 receptor blockers (i.e. sartanes) and/or AT2 agonists in prostate cancer prophylaxis and/or treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.